Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 2, 2012, Pages 376-388

  Grossini, Elena ^a   Molinari, Claudio ^a   Pollesello, Piero ^b   Bellomo, Giorgio ^c   Valente, Guido ^a   Mary, David ^a   Vacca, Giovanni ^a   Caimmi, Philippe ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b ORION CORPORATION   (Finland)

^c Laboratory Analysis   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); CASPASE 3; CASPASE 9; CYTOCHROME C; EXTRACELLULAR SUPEROXIDE DISMUTASE; GLUTATHIONE; HTK SOLUTION; LEVOSIMENDAN; N ACETYL BETA GLUCOSAMINIDASE; PROTEIN BAX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME RELEASE; FUNCTIONAL ASSESSMENT; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY PRESERVATION; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; TREATMENT RESPONSE;

ACUTE KIDNEY INJURY; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CELL SURVIVAL; DECANOIC ACIDS; GLUCOSE; HYDRAZONES; HYDROXY ACIDS; KATP CHANNELS; KIDNEY; MANNITOL; MITOCHONDRIA; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POTASSIUM CHLORIDE; PROCAINE; PYRIDAZINES; REPERFUSION INJURY; SWINE;

EID: 84864124308     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.193961     Document Type: Article

References (50)

1. Aronson S and Blumenthal R (1998) Perioperative renal dysfunction and cardiovascular anesthesia: concerns and controversies. J Cardiothorac Vasc Anesth 12:567-586. (Pubitemid 28473821)
2. Assad AR, Delou JM, Fonseca LM, Villela NR, Nascimento JH, Verçosa N, Lopes AG, and Capella MA (2009) The role of KATP channels on propofol preconditioning in a cellular model of renal ischemia-reperfusion. Anesth Analg 109:1486-1492.
3. 2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 7:882-887.
4. Bonventre JV (1993) Mechanisms of ischemic acute renal failure. Kidney Int 43:1160-1178.
5. Bonventre JV (2002) Kidney ischemic preconditioning. Curr Opin Nephrol Hypertens 11:43-48.
6. Boom H, Mallat MJ, de Fijter JW, Zwinderman AH, and Paul LC (2000) Delayed graft function influences renal function, but not survival. Kidney Int 58:859-866. (Pubitemid 30620036)
7. Caimmi PP, Kapetanakis EI, Beggino C, Molinari C, Giustini G, Crosio E, Reposo G, Micalizzi E, Vacca G, and Grossini E (2011a) Management of acute cardiac failure by intracoronary administration of levosimendan. J Cardiovasc Pharmacol 58:246-253.
8. Caimmi PP, Molinari C, Uberti F, Micalizzi E, Valente G, Mary DA, Vacca G, and Grossini E (2011b) Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg 39:e59-67.
9. Cancherini DV, Trabuco LG, Rebouças NA, and Kowaltowski AJ (2003) ATP-sensitive K+ channels in renal mitochondria. Am J Physiol Renal Physiol 285: F1291-F1296.
10. Chintala MS, Chiu PJ, Vemulapalli S, Watkins RW, and Sybertz EJ (1993) Inhibition of endothelial derived relaxing factor (EDRF) aggravates ischemic acute renal failure in anesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 348:305-310. (Pubitemid 23271634)
11. Damman K and Voors AA (2007) Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. Editorial to: "levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine by Yilmaz et al." Cardiovasc Drugs Ther 21:403-404. (Pubitemid 50004695)
12. Devalaraja-Narashimha K, Singaravelu K, and Padanilam BJ (2005) Poly(ADP-ribose) polymerase-mediated cell injury in acute renal failure. Pharmacol Res 52:44-59. (Pubitemid 40725599)
13. Dhalla NS, Elmoselhi AB, Hata T, and Makino N (2000) Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res 47:446-456. (Pubitemid 30646067)
14. García González MJ and Domínguez Rodríguez A (2006) Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan. Am J Cardiovasc Drugs 6:69-75.
15. Grossini E, Caimmi PP, Molinari C, Teodori G, and Vacca G (2005) Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig. J Cardiovasc Pharmacol 46:333-342. (Pubitemid 41262836)
16. Grossini E, Caimmi PP, Platini F, Molinari C, Uberti F, Cattaneo M, Valente G, Mary DA, Vacca G, and Tessitore L (2010) Modulation of programmed forms of cell death by intracoronary levosimendan during regional myocardial ischemia in anesthetized pigs. Cardiovasc Drugs Ther 24:5-15.
17. Grossini E, Molinari C, Caimmi PP, Uberti F, and Vacca G (2009) Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATP channel. Br J Pharmacol 156:250-261.
18. Haikala H, Kaheinen P, Levijoki J, and Lindén IB (1997) The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 34:536-546. (Pubitemid 27272673)
19. Hrabalová M, Bachleda P, Lubuská L, Kojecký Z, Zadrazil J, Krejcí K, and Al Jabry S (2003) Effect of various protective solutions on function after kidney transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147:197-202.
20. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
21. Javadov S and Karmazyn M (2007) Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem 20:1-22. (Pubitemid 46956808)
22. Jones SP, Hoffmeyer MR, Sharp BR, Ho YS, and Lefer DJ (2003) Role of intracellular antioxidant enzymes after in vivo myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 284:H277-H282. (Pubitemid 36076295)
23. Kaheinen P, Pollesello P, Levijoki J, and Haikala H (2001) Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 37:367-374. (Pubitemid 32240418)
24. Kawakami T, Puri N, Sodhi K, Bellner L, Takahashi T, Morita K, Rezzani R, Oury TD and Abraham NG (2012) Reciprocal effects of oxidative stress on heme oxygenase expression and activity contributes to reno-vascular abnormalities in EC-SOD knockout mice. Int J Hypertens, http://dx.doi.org/10.1155/2012/740203.
25. Kersten JR, Montgomery MW, Pagel PS, and Warltier DC (2000) Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of KATP channels. Anesth Analg 90:5-11. (Pubitemid 30022959)
26. Klaus F, Castro DB, Bittar CM, Bittar AE, Keitel E, Seelig DC, Goldani JC, Meinne MH, and Garcia VD (2007) Kidney transplantation with Belzer or Custodiol solution: a randomized prospective study. Transplant Proc 39:353-354. (Pubitemid 46386230)
27. Lameire N and Vanholder R (2001) Pathophysiologic features and prevention of human and experimental acute tubular necrosis. J Am Soc Nephrol 12:S20-S32. (Pubitemid 32119050)
28. Lien YH, Lai LW, and Silva AL (2003) Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice. Life Sci 74:543-552.
29. Linden RJ and Mary DASG (1983) The preparation and maintenance of anaesthetized animals for the study of cardiovascular function, in Techniques in Cardiovascular Physiology (Linden RJ ed) vol P3/1, pp 1-22, Science Publishers, Shannon, Ireland.
30. Matsumura Y, Nishiura M, Deguchi S, Hashimoto N, Ogawa T, and Seo R (1998) Protective effect of FK409, a spontaneous nitric oxide releaser, on ischemic acute renal failure in rats. J Pharmacol Exp Ther 287:1084-1091. (Pubitemid 29131624)
31. McCombs PR and Roberts B (1979) Acute renal failure following resection of abdominal aortic aneurysm. Surg Gynecol Obstet 148:175-178. (Pubitemid 9132181)
32. Meagher EA and FitzGerald GA (2000) Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med 28:1745-1750. (Pubitemid 30628661)
33. Molitoris BA, Sandoval R, and Sutton TA (2002) Endothelial injury and dysfunction in ischemic acute renal failure. Crit Care Med 30:S235-S240. (Pubitemid 34507997)
34. Mundel P, Bachmann S, Bader M, Fischer A, Kummer W, Mayer B, and Kriz W (1992) Expression of nitric oxide synthase in kidney macula densa cells. Kidney Int 42:1017-1019.
35. Nilakantan V, Liang H, Mortensen J, Taylor E, and Johnson CP (2010) Variable effects of the mitoKATP channel modulators diazoxide and 5-HD in ATP-depleted renal epithelial cells. Mol Cell Biochem 335:211-222.
36. Przyklenk K and Kloner RA (1986) Superoxide dismutase plus catalase improve contractile function in the canine model of the "stunned myocardium". Circ Res 58:148-156. (Pubitemid 16165941)
37. Ruilope LM, Lahera V, Rodicio JL, and Romero JC (1994) Participation of nitric oxide in the regulation of renal function: possible role in the genesis of arterial hypertension. J Hypertens 12:625-631. (Pubitemid 24211281)
38. Schneider MP, Sullivan JC, Wach PF, Boesen EI, Yamamoto T, Fukai T, Harrison DG, Pollock DM, and Pollock JS (2010) Protective role of extracellular superoxide dismutase in renal ischemia/reperfusion injury. Kidney Int 78:374-381.
39. Shultz PJ, Tayeh MA, Marletta MA, and Raij L (1991) Synthesis and action of nitric oxide in rat glomerular mesangial cells. Am J Physiol Renal Physiol 261:F600-F606.
40. Snoeijs MG, van Bijnen A, Swennen E, Haenen GR, Roberts LJ 2nd, Christiaans MH, Peppelenbosch AG, Buurman WA, and Ernest van Heurn LW (2011) Tubular epithelial injury and inflammation after ischemia and reperfusion in human kidney transplantation. Ann Surg 253:598-604.
41. Soeding PF, Crack PJ, Wright CE, Angus JA, and Royse CF (2011) Levosimendan preserves the contractile responsiveness of hypoxic human myocardium via mitochondrial KATP channel and potential pERK 1/2 activation. Eur J Pharmacol 655:59-66.
42. Star RA (1998) Treatment of acute renal failure. Kidney Int 54:1817-1831.
43. Sun Z, Zhang X, Ito K, Li Y, Montgomery RA, Tachibana S, and Williams GM (2008) Amelioration of oxidative mitochondrial DNA damage and deletion after renal ischemic injury by the KATP channel opener diazoxide. Am J Physiol Renal Physiol 294:F491-F498. (Pubitemid 351442218)
44. Sutton TA, Fisher CJ, and Molitoris BA (2002) Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 62:1539-1549. (Pubitemid 35286261)
45. Terada Y, Tomita K, Nonoguchi H, and Marumo F (1992) Polymerase chain reaction localization of constitutive nitric oxide synthase and soluble guanylate cyclase messenger RNAs in microdissected rat nephron segments. J Clin Invest 90:659-665.
46. Uberti F, Caimmi PP, Molinari C, Mary D, Vacca G, and Grossini E (2011) Levosimendan modulates programmed forms of cell death through KATP channels and nitric oxide. J Cardiovasc Pharmacol 57:246-258.
47. Yakut N, Yasa H, Bahriye Lafci B, Ortac R, Tulukoglu E, Aksun M, Ozbek C, and Gurbuz A (2008) The influence of levosimendan and iloprost on renal ischemia-reperfusion: an experimental study. Interact Cardiovasc Thorac Surg 7:235-239. (Pubitemid 351497552)
48. Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, Yilmaz A, and Tandogan I (2007) Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 21:431-435. (Pubitemid 350231513)
49. Zweier JL, Broderick R, Kuppusamy P, Thompson-Gorman S, and Lutty GA (1994) Determination of the mechanism of free radical generation in human aortic endothelial cells exposed to anoxia and reoxygenation. J Biol Chem 269:24156-24162. (Pubitemid 24300954)
50. Zweier JL and Talukder MA (2006) The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 70:181-190.